Research Grid – Weekly Recap

Research Grid spent the week spotlighting its role as an AI-enabled, patient-centric infrastructure provider for clinical research, with updates spanning cardiology, neurology, and rare disease. The company continued to emphasize technology that streamlines trial operations alongside community partnerships that aim to improve study design and patient engagement.

In cardiology, Research Grid highlighted a real-world deployment of its AI platform in a cardiac imaging trial of more than 600 patients at Queen Mary University of London and Barts Health NHS Trust. The system reportedly automated data entry from thousands of handwritten and scanned records, suggesting potential savings of about $1.5 million and more than 24,000 staff hours while improving data quality.

The company framed this cardiac study as evidence that its traceable AI models are moving from lab concepts into live clinical workflows using real patient data. If similar efficiencies are replicated, the platform could appeal to hospitals, academic centers, and CROs seeking to cut structural costs in research operations and redeploy skilled staff away from repetitive administrative tasks.

Beyond operational efficiency, Research Grid underscored a global patient and community network that it says spans 157 countries and roughly 442 million members. By involving community partners earlier, the firm reports a 145% increase in patient engagement, positioning its community-first model as a response to industry data showing that 80–85% of trials miss enrollment targets and many sites fail to recruit any participants.

In neurology, multiple posts focused on Parkinson’s disease, citing biomarker advances backed by The Michael J. Fox Foundation and large initiatives like the Parkinson’s Progression Markers Initiative. Research Grid cast itself as a connector between groups such as Parkinson’s UK and Cure Parkinson’s and trial sponsors, aiming to support more targeted, progression-focused studies that reflect real-world patient experience.

The company also highlighted work in Sjögren’s syndrome, partnering with patient-led group Sjogren’s India to address diagnostic delays and social stigma around this often “invisible” condition. By offering its community network to groups free of charge, Research Grid is positioning these collaborations as a source of real-world insight for sponsors prioritizing inclusive and representative study designs.

In haemophilia, Research Grid’s communications drew attention to emerging RNA-based therapies, anti-TFPI agents, and gene therapies that could reduce treatment burden and improve long-term outcomes. While no specific commercial contracts were disclosed, the firm presented itself as operating at the intersection of advanced therapeutics, clinical research, and lived experience in high-need, specialty indications.

Taken together, the week’s messaging outlined a strategy built on three pillars: AI-driven efficiency in data-heavy trials, a scaled global community network, and alignment with complex conditions like Parkinson’s, Sjögren’s syndrome, and haemophilia. If the company can translate these capabilities into contracted deployments, it could strengthen its positioning in the clinical research technology and real-world evidence markets.